Additional induction chemotherapy to concurrent chemotherapy and intensity-modulated radiotherapy with or without nimotuzumab in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis

Conclusions: Nimotuzumab is an effective treatment option for locoregionally advanced nasopharyngeal carcinoma, and the addition of induction chemotherapy to concurrent chemoradiotherapy and nimotuzumab could obtain the best survival benefits.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research

Related Links:

Conclusion: Although the number of study population was small, our results suggest that PCE is feasible and potentially effective for R/M NPC, with a 58.3% response rate and 4.1-month PFS. Further prospective evaluation is warranted.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study sought to investigate the impact of tumor volume enlargement after IC on the dosimetric parameters of subsequent radiotherapy. The records of a total of 240 locally advanced NPC patients who received IC followed by concurrent chemoradiotherapy were retrospectively reviewed. Patients with a tumor volume enlargement of ≥10% and patients with a tumor volume reduction of ≥10% after induction chemotherapy were classified as the enlargement group and the control group, respectively. The dosimetric parameters of the planning target volumes (PTVs) and the organs at risk (OARs) were compared between the matched gro...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Conclusion: The half-life clearance of plasma EBV DNA was prognostic in non-metastatic NPC staged and treated in the contemporary era. Earlier biomarker surveillance during treatment should be considered.Clinical Trial Registration: This study has been registered with ClinicalTrials.gov (Identifier: NCT03830996).
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Condition:   Nasopharyngeal Carcinoma Interventions:   Drug: Toripalimab;   Radiation: IMRT to the nasopharynx and neck;   Drug: Gemcitabine and Cisplatin Chemotherapy;   Drug: Adjuvant chemotherapy with Capecitabine Sponsors:   Fudan University;   Fudan University Eye and ENT Hospital;   Anhui Provincial Hospital;   Sir Run Run Shaw Hospital;   Hangzhou Cancer Hospital;   Ningbo Medical Center Lihuili ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSION: Bevacizumab 7.5mg/kg with cisplatin and gemcitabine was well tolerated. Promising tumour response was observed and supported mechanistically by positive effects on tumour perfusion and immune cell trafficking into the tumour. PMID: 32816944 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Conclusions: The underreporting and inconsistent reporting of toxicities would significantly impair the assessment of value using any framework. Moreover, there is a concern that the ASCO framework generated highly inconsistent scoring for treatments that met the ESMO criteria for a high level of benefit. The anomalies identified in the frameworks function would be helpful in their future improvement.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Mi-Jo Lee, Hyun-Jin SonJournal of Cancer Research and Therapeutics 2020 16(3):653-656 Nasopharyngeal sarcomatoid carcinoma (SaCa) is extremely rare, and concurrent chemoradiation is the standard treatment for squamous cell-based nasopharyngeal cancer (NPC). This case report gives the first explanation of a nasopharyngeal SaCa patient treated with volumetric modulated arc therapy (VMAT) with simultaneous integrated boost (SIB), which is an excellent treatment modality that leads to complete response for locally advanced NPC. A 70-year-old male presented with nasal obstruction, epistaxis, and right neck node enlargements. E...
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
ConclusionsThese data indicate that SP and FP therapies have similar efficacy in treating LA ‐NPC. The SP regimen showed a tolerable safety profile along with a lower frequency of severe OM and therefore, an improved life quality. In conclusion, SP was a well tolerated, effective, regimen for LA‐NPC treatment.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Our study shows the distribution patterns and prognoses of distant metastases among 4 histological types in NPC. A nomogram was constructed for clinical use based on 4 independent prognostic risk indicators, including histology, radiation therapy, chemotherapy and metastatic status. Our findings provide a reference for clinical decision ‐making and future diagnostic screening tests for NPC with distant metastases. AbstractCurrently, the features and prognosis of nasopharyngeal carcinoma (NPC) with distant metastases are still rarely reported. Thus, the main purpose of our study was to investigate the metastasis patterns ...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Conditions:   Metastatic Nasopharyngeal Carcinoma;   Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Metastatic Nasopharyngeal Undifferentiated Carcinoma;   Nasopharyngeal Nonkeratinizing Carcinoma;   Recurrent Nasopharyngeal Carcinoma;   Recurrent Nasopharyngeal Keratinizing Squa mous Cell Carcinoma;   Recurrent Nasopharyngeal Undifferentiated Carcinoma;   Stage IV Nasopharyngeal Carcinoma AJCC v8;   Stage IVA Nasopharyngeal Carcinoma AJCC v8;   Stage IVB Nasopharyng...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Nasopharyngeal Cancer | Study